FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindness
transurfer/iStock via Getty Images         

RegeneronÂ Pharmaceuticals (NASDAQ:REGN) on Wednesday said the U.S. FDA had accepted its application requesting for an extended regimen for its Eylea injection to treat patients with diabetic retinopathy (DR).
DR is when high blood sugar in diabetic patients damages the blood vessels in the retina.
REGN's supplemental biologics license application is requesting a 16-week 2 mg dosing regimen for DR patients.
Eylea is already approved to be used in a 4- and 8-week dosing regimen for DR patients.
The FDA is set to decide on the supplemental application on or before Feb. 28, 2023.
REGN stockÂ +1.1%Â at $600.83 in morning trading.